Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
ContributorsDeodhar, Atul; Helliwell, Philip S; Boehncke, Wolf-Henning; Kollmeier, Alexa P; Hsia, Elizabeth C; Subramanian, Ramanand A; Xu, Xie L; Sheng, Shihong; Agarwal, Prasheen; Zhou, Bei; Zhuang, Yanli; Ritchlin, Christopher T; DISCOVER-1 Study Group
Published inLancet, vol. 395, no. 10230, p. 1115-1125
Publication date2020
Abstract
Keywords
- Adult
- Antibodies
- Monoclonal
- Humanized/therapeutic use
- Arthritis
- Psoriatic/drug therapy
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Severity of Illness Index
- Treatment Outcome
- Tumor Necrosis Factor-alpha/antagonists & inhibitors
Affiliation entities
Research groups
Citation (ISO format)
DEODHAR, Atul et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. In: Lancet, 2020, vol. 395, n° 10230, p. 1115–1125. doi: 10.1016/S0140-6736(20)30265-8
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:154812
- DOI : 10.1016/S0140-6736(20)30265-8
- PMID : 32178765
Journal ISSN0140-6736
